Human primary CD34+ hematopoietic stem and progenitor cells

Ended Purchase Order Awarded Last action

Contract number
75F40120P00616
Awardee
Awarding agency
Obligated
$94,003

Award facts

Opportunity
Contract value 100% obligated
$94,003.45 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Competed under SAP · 1 offer Simplified Acquisition
Pricing
Firm Fixed Price
Place of performance
Los Angeles, CA 91325, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Close Out P00001 -$997
Original award $95,000

About this award

The U.S. Food and Drug Administration (FDA) awarded a Firm Fixed Price Purchase Order contract worth $94,003.45 to Charles River Laboratories Cell Solutions, Inc. for the provision of human primary CD34+ hematopoietic stem and progenitor cells. This contract supports the FDA's Center for Biologics Evaluation and Research (CBER), Division of Cell and Gene Therapy (DCGT) in conducting critical path research to develop and promote technology for the regulation of cellular and genetic therapeutics. The contract has an ultimate completion date of September 7, 2021 and was awarded on September 8, 2020. No set-aside designation was used for this contract.

Quick answers

Who was awarded contract 75F40120P00616?

75F40120P00616 was awarded to Charles River Laboratories Cell Solutions, Inc. by Food and Drug Administration (Department of Health and Human Services) on September 8, 2020.

How much is contract 75F40120P00616 worth?

The government has obligated $94,003 on 75F40120P00616.

Was contract 75F40120P00616 competed?

The extent of competition for 75F40120P00616 was competed under sap. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award